Closed · PA-06-349 · CFDA 93.396 · Discretionary
Memory T Lymphocytes in Cancer Immunology (R21)
Federal grant opportunity posted by National Institutes of Health, cataloged on Grants.gov.
- up to $200K
- Award range
- Closed
- Status
- -
- Close date
- -
- Expected awards
The verdict
Memory T Lymphocytes in Cancer Immunology (R21) is a closed discretionary listing from National Institutes of Health that offered Up to $200,000. Future funding cycles may be published under the same CFDA number.
- up to $200K
- award range
- Closed
- application status
- 93.396
- CFDA program
Opportunity snapshot. This Grants.gov announcement - Memory T Lymphocytes in Cancer Immunology (R21) - is cataloged under number PA-06-349 and tied to CFDA assistance listing 93.396, posted by National Institutes of Health. Grants.gov currently shows the opportunity as closed, first posted on April 13, 2006 and last updated on December 5, 2008. The funding category is Discretionary, delivered as a grant.
Award economics. The award range on file is Up to $200,000. Cost sharing is not required, so applicants do not need to commit matching funds to be competitive on this opportunity. Federal award ranges are often upper bounds; actual allocations reflect program appropriations, the strength of the applicant pool, and the evaluation committee's scoring.
Deadline and action path. This opportunity is closed. Monitoring the parent program page is the most reliable way to catch re-announcements in the next funding cycle. Every Grants.gov submission requires an active SAM.gov registration and a Unique Entity ID. Review the Eligibility section below carefully, federal eligibility categories (nonprofit, state or local government, tribal, individual, educational institution, small business) have distinct registration and reporting requirements. Pre-application outreach to the listed agency contact is permitted and often welcomed, it helps clarify scope and scoring priorities. Before acting on the deadline or award figures above, verify them directly on the official Grants.gov listing, amendments can change dates and amounts after this page was last refreshed.
Award Range
Up to $200,000
Close Date
Not specified
Multiple Receipt Dates - See Link to Full Announcement for details.
Posted
April 13, 2006
Instrument
Grant
Description
- This funding opportunity announcement (FOA) solicits Exploratory/Developmental (R21) grant applications from applicant organizations that propose to conduct basic research studies that are relevant to anti-tumor immunity and that are focused on memory T lymphocytes and/or the cells and molecules that interact with memory T lymphocytes. Such research may include investigations of T memory cell differentiation, maintenance, and re-activation. Investigations may entail both human and animal studies, and both in vitro and in vivo analyses. Innovative uses of existing technologies and reagents, as well as the development of new technologies and reagents, are encouraged. We anticipate that the results of such research will ultimately improve the prospects for successful cancer immunotherapies and cancer vaccine development.-This FOA will utilize the Exploratory/Developmental (R21) grant mechanisms and runs in parallel with a FOA of identical scientific scope, PA-06-350, that solicits applications under the R01 mechanism.-Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications. Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total amount awarded and the number of awards will depend upon the mechanism numbers, quality, duration, and costs of the applications received.-The total project period for an application submitted in response to this funding opportunity may not exceed two years. Direct costs are limited to $275,000 over an R21 2-year period, with no more than $200,000 in direct costs allowed in any single year.-Eligible organizations include: for profit organizations; non-profit organizations; public or private institutions, such as universities, colleges, hospitals and laboratories; units of State governments; units of local governments; eligible institutions of the Federal government; domestic institutions; and foreign institutions. -Eligible Project Directors/Principal Investigators (PD/PIs): Any individual with the skills, knowledge, and resources necessary to carry out the proposed research is invited to work with their institution to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.-Applicants may submit more than one application, provided each application is scientifically distinct
Eligibility
Grants.gov lists this opportunity under eligibility category codes 00, 01, 02, 04, 05, 06, 07, 08, 11, 12, 13, 20, 22, 25. These codes correspond to applicant types (state/local government, tribal organization, nonprofit, educational institution, individual, small business, etc.) defined in Grants.gov's own eligibility reference. See the current Grants.gov eligibility categories or check the official listing below for this opportunity's exact eligibility statement.
Official Listing on Grants.gov
View full details, application forms, and submission instructions.
Agency Contact
NIH OER Webmaster FBOWebmaster@OD.NIH.GOV
Key Dates
Frequently Asked Questions
What is this grant opportunity?
Is this opportunity still open?
How much funding is available?
How do I apply?
More from National Institutes of Health
Clinical Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative UG3/UH3 Clinical Trial Required)
Single-Site Investigator-Initiated Clinical Trials (R61/R33 Clinical Trial Required)
Data Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative U24 Clinical Trial Required)
Development of Collaborative Research Facilities or Research-Resource Facilities (C06 Clinical Trial Not Allowed)
Research Grants in Clinical Informatics (R01 Clinical Trial Optional)
Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.
Read our methodology - how this data is sourced, computed, and verified.
Related
| Publisher | PlainGrants |
| Sources | the SAM.gov Assistance Listings and Grants.gov |